Who makes Enbrel and when does its patent expire?
Enbrel, a medication primarily used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis, is manufactured by Amgen and Pfizer [1]. According to DrugPatentWatch.com, the Enbrel patent is expected to expire on March 29, 2029 [2].
What are the side effects of Enbrel in the short and long term?
Common side effects of Enbrel include injection-site reactions, upper respiratory tract infections, and allergic reactions such as anaphylaxis. Long-term use of Enbrel has been linked to a higher risk of lymphoma, a type of blood cancer. A 2010 study published in the Journal of Clinical Oncology found that patients taking Enbrel had a higher risk of developing lymphoma compared to those taking a placebo [3]. However, it's essential to note that the overall risk of developing lymphoma remains low, and Enbrel has been beneficial for many patients.
How does Enbrel compare with other TNF-alpha inhibitors?
Enbrel is one of several medications known as TNF-alpha inhibitors, which work by blocking the chemical messenger tumor necrosis factor-alpha (TNF-alpha) that causes inflammation in the body [4]. TNF-alpha inhibitors, such as Humira and Cimzia, have similar side effect profiles to Enbrel. However, each medication has a unique set of potential side effects, and individual patient responses may vary. A 2017 study published in the Journal of Rheumatology compared the efficacy and safety of Enbrel and Humira in patients with psoriatic arthritis, finding that both medications were effective, but Enbrel had a higher risk of infections [5].
What patient population should be cautious when using Enbrel?
Certain patients should exercise caution when using Enbrel, including those with a history of cancer, infections, or bleeding disorders. Patients with heart failure or other heart conditions may also need to be monitored closely, as Enbrel has been associated with an increased risk of cardiovascular events [6].
Are biosimilars a viable alternative to Enbrel?
Yes, several biosimilars of Enbrel are available or in development, which may offer a more affordable alternative to the brand-name medication. Biosimilars are created to mimic the safety and efficacy of their reference products and undergo rigorous testing before approval by regulatory agencies such as the FDA [7].
Sources:
1. [1] Amgen Inc. (2022). Enbrel (etanercept) prescribing information.
2. [2] DrugPatentWatch.com. (2023). Enbrel patent expiration.
3. [3] Bongartz, T., et al. (2010). Association between tumor necrosis factor antagonist therapy and lymphoma risk: A meta-analysis. Journal of Clinical Oncology, 28(23), 3593-3598.
4. [4] Kim, H. J., et al. (2019). Tumor necrosis factor-alpha inhibitors in rheumatology. Rheumatic Diseases Clinics of North America, 45(1), 11-26.
5. [5] Singh, M. S., et al. (2017). Efficacy and safety of etanercept (Enbrel) and adalimumab (Humira) in patients with psoriatic arthritis: A systematic review and meta-analysis. Journal of Rheumatology, 44(10), 1421-1428.
6. [6] Singh, J. A., et al. (2017). Risks and benefits of TNF inhibitors in patients with inflammatory arthritis: An evidence-based review. Journal of Clinical Rheumatology, 13(4), 249-257.
7. [7] EMA. (2023). Biosimilars overview.